Acquisitions, Collaboration, License and Other Strategic Agreements - Narrative (Details) $ in Thousands					1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2021 USD ($)	Aug. 06, 2020 USD ($)	May 21, 2020 USD ($) day	Jan. 16, 2019 USD ($)	Jul. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement termination payment		$ 12,500
Option period to third party supplier to acquire study		9 months
Loss on disposal of assets, net							$ 35,400	$ 0	$ 20,956	$ 0
Velo Bio, LLC | Regulatory Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 5,000
Velo Bio, LLC | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						30,000
Velo Bio, LLC | Annual Sales Milestone Achievements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						240,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone targets						900,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone targets						300,000
Velo Bio, LLC | Commercial Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments						$ 10,000
Ciraparantag | Norgine B.V.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds related to collaborative arrangement					$ 30,000
Potential milestone proceeds from collaborative arrangement payable to equity holders					40,000
Ciraparantag | Norgine B.V. | Regulatory Milestone Achievement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement					70,000
Ciraparantag | Norgine B.V. | Sales Milestones Achievement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement					190,000
Intrarosa | Millicent Pharma Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds related to collaborative arrangement			$ 20,900
Loss on disposal of assets, net							(14,400)		(14,400)
Intrarosa | Millicent Pharma Limited | Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Transaction Fees
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative arrangement									2,500
Intrarosa | Millicent Pharma Limited | Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Carrying Value Of Assets Sold And Other Costs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative arrangement									4,000
Intrarosa | Millicent Pharma Limited | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement			105,000
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $65 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement			$ 25,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day			12
Potential milestone proceeds, triggering event, sales			$ 65,000
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $115 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement			$ 35,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day			12
Potential milestone proceeds, triggering event, sales			$ 115,000
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $175 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement			$ 45,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day			12
Potential milestone proceeds, triggering event, sales			$ 175,000
Vyleesi Products | Palatin Technologies, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss on disposal of assets, net							$ 22,400		22,400
Early contract termination fees					$ 12,000
Assets and other costs carrying value, recognized in loss of disposal of assets									$ 6,100
Vyleesi Products | Palatin Technologies, Inc. | Subsequent Event | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Early contract termination fees	$ 4,300
Perosphere Pharmaceuticals Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)				$ 365,000
Perosphere Pharmaceuticals Inc. | Regulatory Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)				$ 140,000
Credited percentage				50.00%
Perosphere Pharmaceuticals Inc. | Sales Milestones Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)				$ 225,000
Perosphere Pharmaceuticals Inc. | Milestone Achievement, Approval by European Medicines Agency
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)				40,000
Perosphere Pharmaceuticals Inc. | First Sales Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration, milestone payment				20,000
Potential milestone payment, triggering event, sales				$ 100,000